Atogepant Reduces Psychological Dependence on Acute Treatments Evaluated With the Leeds Dependence Questionnaire: A Prospective Study [PDF]
Brain and BehaviorBackground The Leeds Dependence Questionnaire (LDQ) is a validated tool for assessing psychological dependence across various substances and has been adapted for use in headache patients.
Luigi Francesco Iannone +6 more
doaj +3 more sources
Oral atogepant mitigates spreading depolarization-induced pain and anxiety behavior in mice [PDF]
The Journal of Headache and PainBackground Spreading depolarization (SD) is the most likely cause of migraine aura and may be linked to trigeminal nociception. Using minimally invasive optogenetic SD induction (opto-SD), we previously showed that SD triggers acute periorbital ...
Melih Z. Kaya +3 more
doaj +3 more sources
Cephalalgia Reports, 2023 Background/Hypothesis: Atogepant, an oral calcitonin gene-related peptide receptor antagonist, is approved for the preventive treatment of migraine in adults.
Ramesh Boinpally +11 more
doaj +2 more sources
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response [PDF]
The Journal of Headache and PainBackground Atogepant is approved for migraine prevention and has shown strong efficacy in clinical trials. However, its effectiveness following failure of anti-CGRP monoclonal antibodies (MAbs) has not been evaluated in large real-world populations ...
Albert Muñoz-Vendrell +31 more
doaj +3 more sources
One-month atogepant treatment induces rapid changes in delta-band functional connectivity in migraine: an HD-EEG study [PDF]
The Journal of Headache and PainBackground Atogepant is a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the preventive treatment of migraine. While its peripheral mechanisms are well characterized, little is known about its potential effects on ...
Matteo Conti +8 more
doaj +3 more sources
Efficacy and safety of atogepant in prophylactic treatment of migraine: a Meta-analysis [PDF]
Yixue xinzhi zazhiObjective To evaluate the efficacy and safety of atogepant in the prophylactic treatment of migraine.Methods The randomized controlled trials (RCTs) of atogepant in the prophylactic treatment of migraine were collected by searching PubMed, Embase ...
SHE Lang +3 more
doaj +2 more sources
Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials [PDF]
The Journal of Headache and PainBackground Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability.
Paul Rizzoli +11 more
doaj +3 more sources
Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase 3, Open-Label, 52-Week Extension Study [PDF]
Neurology and TherapyIntroduction Atogepant is an oral calcitonin gene-related peptide receptor antagonist approved in the USA, EU, and Japan for the preventive treatment of migraine in adults. We evaluated the long-term safety, efficacy, and functional outcomes of atogepant
Yasuhiko Matsumori +10 more
doaj +2 more sources
Atogepant: Mechanism of action, clinical and translational science
Clinical and Translational ScienceSince the discovery of calcitonin gene‐related peptide (CGRP) in 1982, its integral role in migraine pathophysiology, specifically migraine pain, has been demonstrated through cumulative scientific discoveries that have led to the development and ...
Ramesh Boinpally +2 more
doaj +2 more sources
The preclinical discovery and development of atogepant for migraine prophylaxis [PDF]
Expert Opinion on Drug DiscoveryAtogepant is a selective calcitonin gene-related peptide (CGRP) receptor antagonist that is utilized in adults for the prevention of episodic and chronic migraine. Cumulative findings support the involvement of CGRP in migraine pathophysiology, and atogepant functions by competitively antagonizing CGRP receptors, which results in the inhibition of ...
Carlo Baraldi +3 more
openaire +4 more sources